News Mixed data mars Sanofi's venglustat programme Sanofi has reported positive phase 3 results with venglustat in Gaucher disease, but the drug missed the mark in a Fabry disease trial.
News Sanofi's venglustat bombs again, but isn't dead yet Shortly after failing a Parkinson's disease study, Sanofi's venglustat has missed the mark in another trial in autosomal dominant polycystic kidney disease (ADPKD), whittling down the list
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
